Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Jordan

Showing results (521-530 of 572) with videos related to

Pageof 58
Sort By:
Elife|May 2, 2025
Correction: <i>TP53</i> drives invasion through expression of its Δ133p53β variantGilles Gadea, Nikola Arsic, Kenneth Fernandes, et al.
Blood|July 24, 2024
Diagnostic guidelines for familial hemophagocytic lymphohistiocytosis revisitedJan-Inge Henter, Elena Sieni, Julia Eriksson, et al.
Blood|April 18, 2019
Recommendations for the management of hemophagocytic lymphohistiocytosis in adultsPaul La Rosée, AnnaCarin Horne, Melissa Hines, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 14, 2015
Experience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends on Underlying Disease, Stem Cell Source, and Alemtuzumab RegimenRebecca A Marsh, Marepalli B Rao, Aharon Gefen, et al.
Elife|September 16, 2016
<i>TP53</i> drives invasion through expression of its Δ133p53β variantGilles Gadea, Nikola Arsic, Kenneth Fernandes, et al.
Scientific Reports|March 29, 2017
Characterisation of male breast cancer: a descriptive biomarker study from a large patient seriesMatthew P Humphries, Sreekumar Sundara Rajan, Hedieh Honarpisheh, et al.
Journal of Clinical Immunology|September 29, 2021
Reduced-Intensity/Reduced-Toxicity Conditioning Approaches Are Tolerated in XIAP Deficiency but Patients Fare Poorly with Acute GVHDDanielle E Arnold, Rofida Nofal, Connor Wakefield, et al.
Blood Advances|April 18, 2025
The OHI index predicts early mortality from organ dysfunction and survival benefit from etoposide in lymphoma patientsAdi Zoref-Lorenz, Jun Murakami, Ronit Gurion, et al.
JAMA|May 13, 2010
Neuropsychological dysfunction and neuroimaging abnormalities in neurologically intact adults with sickle cell anemiaElliott P Vichinsky, Lynne D Neumayr, Jeffrey I Gold, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 24, 2017
Manipulating DNA damage-response signaling for the treatment of immune-mediated diseasesJonathan P McNally, Scott H Millen, Vandana Chaturvedi, et al.
Pageof 58

Showing results (521-530 of 572) with videos related to

Sort By:
Pageof 58
Elife|May 2, 2025
Correction: <i>TP53</i> drives invasion through expression of its Δ133p53β variantGilles Gadea, Nikola Arsic, Kenneth Fernandes, et al.
Blood|July 24, 2024
Diagnostic guidelines for familial hemophagocytic lymphohistiocytosis revisitedJan-Inge Henter, Elena Sieni, Julia Eriksson, et al.
Blood|April 18, 2019
Recommendations for the management of hemophagocytic lymphohistiocytosis in adultsPaul La Rosée, AnnaCarin Horne, Melissa Hines, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 14, 2015
Experience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends on Underlying Disease, Stem Cell Source, and Alemtuzumab RegimenRebecca A Marsh, Marepalli B Rao, Aharon Gefen, et al.
Elife|September 16, 2016
<i>TP53</i> drives invasion through expression of its Δ133p53β variantGilles Gadea, Nikola Arsic, Kenneth Fernandes, et al.
Scientific Reports|March 29, 2017
Characterisation of male breast cancer: a descriptive biomarker study from a large patient seriesMatthew P Humphries, Sreekumar Sundara Rajan, Hedieh Honarpisheh, et al.
Journal of Clinical Immunology|September 29, 2021
Reduced-Intensity/Reduced-Toxicity Conditioning Approaches Are Tolerated in XIAP Deficiency but Patients Fare Poorly with Acute GVHDDanielle E Arnold, Rofida Nofal, Connor Wakefield, et al.
Blood Advances|April 18, 2025
The OHI index predicts early mortality from organ dysfunction and survival benefit from etoposide in lymphoma patientsAdi Zoref-Lorenz, Jun Murakami, Ronit Gurion, et al.
JAMA|May 13, 2010
Neuropsychological dysfunction and neuroimaging abnormalities in neurologically intact adults with sickle cell anemiaElliott P Vichinsky, Lynne D Neumayr, Jeffrey I Gold, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 24, 2017
Manipulating DNA damage-response signaling for the treatment of immune-mediated diseasesJonathan P McNally, Scott H Millen, Vandana Chaturvedi, et al.
Pageof 58